Gregory Stone, PhD

Director of Microbiology
Pfizer, Inc.

Disclosure(s): No financial relationships to disclose

Poster(s):

• 1673 - In vitro Activities of Ceftaroline and Comparator Agents against Bacterial Pathogens Frequently Causing Community-Acquired Respiratory Tract Infections in Patients from a Global Population: ATLAS Surveillance Program 2017-2020
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1707 - In vitro Activities of Ceftazidime-Avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected < 48 Hours and ≥48 Hours Post-Admission from Hospitalized Adult Patients, ATLAS Global Surveillance Program 2017-2020
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1708 - In vitro Activities of Ceftazidime-Avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected < 48 Hours and ≥48 Hours Post-Admission from Hospitalized Pediatric Patients, ATLAS Global Surveillance Program 2017-2020
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1709 - In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against MDR Enterobacterales and Pseudomonas aeruginosa Collected in Latin America, ATLAS Global Surveillance Program 2018-2020
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1719 - In Vitro Activity of Ceftazidime-avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected from Patients with Bloodstream Infections as Part of the ATLAS Global Surveillance Program, 2017-2020
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET